Revance Therapeutics, Inc. (RVNC)
Statistics
Key valuation multiples, financial performance ratios, profitability metrics, and per share data consolidated into a single structured view. Each metric is benchmarked against both industry and sector averages — providing immediate context on whether the company is trading at a premium or discount relative to its direct peers and the broader market segment.
Valuation & Market Metrics
Market Capitalization
381,024,000
EV to revenue ratio (TTM)
2.648
EV to ebitda
-2.257
Financial Performance
Revenue (TTM)
256,945,000
Gross profit (TTM)
103,688,000
EBITDA
-187,624,000
Profitability
Operating margin (TTM)
-53.90%
Profit margin
-71.80%
Return on assets (TTM)
-24.40%
Return on equity (TTM)
-2,097.00%
Per Share Metrics
Revenue per share (TTM)
2.66
EPS
-3.34
Diluted EPS (TTM)
-3.34
Book value
-1.55
Dividend per share
Dividend yield
Valuation Multiples
P/E ratio
Trailing P/E
Forward P/E
PEG ratio
-0.64
Price to sales ratio (TTM)
1.483
Price to book ratio (TTM)
12.3
Growth
Quarterly earnings growth (YoY)
10.70%
Quarterly revenue growth (YoY)
0.00%
Analyst Sentiment
Strong buy
Buy
Hold
Sell
Strong sell
Risk & Volatility
Beta
0.953